Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Genzyme Corporation
Private Company Edition: Last year set a high bar for venture capital, but this year is starting strong. Recent VC mega-deals include $500m for EQRx and $230m-plus for Tessera Therapeutics. Also, BioGeneration Ventures closed a €140m ($170.2m) fund and NewAmsterdam raised a $196m series A.
Companies will raise their COVID-19 vaccine prices once the pandemic is over – but key long-term data will determine which comes out on top.
Although there weren’t many large-scale partnerships as in previous years, Korean biopharma firms were involved in a broad range of deals across diverse therapeutic areas in 2020, with ADCs, oncology and domestic alliances emerging as key trends.
Celltrion expects to receive the world’s first approval for a high-concentration adalimumab biosimilar rival to Humira, after receiving a positive opinion from the EMA’s CHMP for its CT-P17 candidate.
- Other Names / Subsidiaries
- ILEX Oncology, Inc.
- Sangstat Medical Corporation